The latest guidance outlines how the Centers for Medicare and Medicaid Services will negotiate with drugmakers to reach agreement on a maximum fair price for a selected medicine, the agency said. It was informed by public input on the initial guidance the agency released in March, which explained how it will select the drugs and how the negotiations will be conducted.
Also, drug companies may publicly discuss the negotiations – the prior secrecy requirement had been a point of contention among manufacturers that was mentioned in the lawsuits. In addition, CMS will hold patient-focused listening sessions to provide drug companies and the public more opportunities to engage with the agency.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Sumber: dcexaminer - 🏆 6. / 94 Baca lebih lajut »
Sumber: WashTimes - 🏆 235. / 63 Baca lebih lajut »
Sumber: dcexaminer - 🏆 6. / 94 Baca lebih lajut »